304
- Knauf H, Mutschler E. Diuretic effectiveness of hydrochlorothiazide and furosemide alone
and in combination in chronic renal failure. J Cardiovasc Pharmacol. 1995;26(3):394–400. - Dussol B, Moussi-Frances J, Morange S, Somma-Delpero C, Mundler O, Berland Y. A pilot
study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage
4 or 5 chronic kidney disease. J Clin Hypertens (Greenwich). 2012;14(1):32–7. - Cirillo M, Marcarelli F, Mele AA, Romano M, Lombardi C, Bilancio G. Parallel-group 8-week
study on chlorthalidone effects in hypertensives with low kidney function. Hypertension.
2014;63(4):692–7. - Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A,
Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A,
Piegas LS, Svendsen TL, Teo KK, Yusuf S, ONTARGET investigators. Renal outcomes with
telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a mul-
ticentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547–53. - Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ,
McCullough PA, O’Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S,
Peduzzi P, Guarino P, VA NEPHRON-D Investigators. Combined angiotensin inhibition for
the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892–903. - Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, AVOID Study Investigators.
Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med.
2008;358(23):2433–46. - Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi
N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA, ALTITUDE
Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med.
2012;367(23):2204–13. - US Food and Drug Administration. FDA drug safety communication: new warning and contra-
indication for blood pressure medicines containing aliskiren (Tekturna). http://www.fda.gov/
Drugs/DrugSafety/ucm300889.htm - Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman
B. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2
diabetes. Clin J Am Soc Nephrol. 2006;1(5):940–51. - Badve SV, Roberts MA, Hawley CM, Cass A, Garg AX, Krum H, Tonkin A, Perkovic V. Effects
of beta-adrenergic antagonists in patients with chronic kidney disease: a systematic review and
meta-analysis. J Am Coll Cardiol. 2011;58(11):1152–61. - Inrig JK. Antihypertensive agents in hemodialysis patients: a current perspective. Semin Dial.
2010;23(3):290–7. - Covic A, Goldsmith D, Donciu MD, Siriopol D, Popa R, Kanbay M, London G. From profu-
sion to confusion: the saga of managing hypertension in chronic kidney disease! J Clin
Hypertens (Greenwich). 2015;17(6):421–7. - K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialy-
sis patients. Am J Kidney Dis. 2005;45(4 Suppl 3):S1–153. - Ichihara A, Hayashi M, Kaneshiro Y, Takemitsu T, Homma K, Kanno Y, Yoshizawa M,
Furukawa T, Takenaka T, Saruta T. Low doses of losartan and trandolapril improve arterial
stiffness in hemodialysis patients. Am J Kidney Dis. 2005;45(5):866–74. - Zannad F, Kessler M, Lehert P, Grünfeld JP, Thuilliez C, Leizorovicz A, Lechat P. Prevention
of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril
and implications for future studies. Kidney Int. 2006;70(7):1318–24. - Moist LM, Port FK, Orzol SM, Young EW, Ostbye T, Wolfe RA, Hulbert-Shearon T, Jones
CA, Bloembergen WE. Predictors of loss of residual renal function among new dialysis
patients. J Am Soc Nephrol. 2000;11(3):556–64. - Matsumoto N, Ishimitsu T, Okamura A, Seta H, Takahashi M, Matsuoka H. Effects of imi-
dapril on left ventricular mass in chronic hemodialysis patients. Hypertens Res.
2006;29(4):253–60.
L. Segall